Want to see JP:4578 full AI Analyst Report?
Otsuka Holdings Co (4578) AI Stock Analysis
Top Page
Otsuka Holdings Co
(TSE/TYO:4578)
The score is driven primarily by strong financial performance—improving profitability and a very low-leverage balance sheet—partly offset by softer recent revenue momentum and some cash conversion variability. Technicals are moderately supportive with price above key moving averages and positive MACD, while valuation is only fair given a ~22.5 P/E and a modest ~1.41% dividend yield.
Otsuka Holdings Co (4578) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 38.41B
- Dividend Yield
- 1.41%
- Average Volume (3M)
- 1.30M
- Price to Earnings (P/E)
- 16.3
- Beta (1Y)
- 0.68
- Revenue Growth
- 11.33%
- EPS Growth
- -12.64%
- Country
- Japan
- Employees
- 37,758
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Otsuka Holdings Co Business Overview & Revenue Model
Company Description
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoim...
How the Company Makes Money
Otsuka Holdings makes money mainly by selling products across two core segments: (1) Pharmaceuticals and (2) Nutraceuticals/consumer health. In Pharmaceuticals, revenue is generated from the commercialization of prescription drugs developed in-house...
Otsuka Holdings Co Earnings Call Summary
The earnings call highlighted strong growth in revenue and business profit, driven by pharmaceutical and nutraceutical segments. Forecasts have been revised upward, and there is an acquisition to further enhance drug discovery capabilities. However, there were some negatives, such as impairment losses and a decrease in certain revenues. Overall, the positive aspects significantly outweigh the negatives, indicating a strong performance and optimistic outlook.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Q2 2024 earnings call for 4578.T, the executives provided detailed guidance reflecting significant growth in both their pharmaceutical and nutraceutical segments. Revenue increased by 17.0% year-on-year to JPY 1,108.9 billion, while business profit surged by 37.8% to JPY 213.6 billion, driven primarily by strong sales of Core 2 pharmaceutical products like ABILIFY MAINTENA and JYNARQUE, and nutraceuticals, particularly in the For Women’s Health category. Despite an impairment loss on AVP-786, net profit rose by 5.1% due to finance income. The company also revised its full-year forecast upwards, with revenue now expected to reach JPY 2,315 billion and business profit JPY 390 billion. Nutraceutical revenue saw a notable increase, achieving over a 20% growth rate to JPY 271.8 billion, fueled by the expansion of products like Bonafide and Nature Made. Additionally, the company announced plans for share repurchases amounting to JPY 50 billion as part of their shareholder return policy.
Otsuka Holdings Co Financial Statement Overview
Summary
Strong overall fundamentals supported by improving profitability (TTM ~72% gross margin, ~14% net margin, ~19% operating margin) and a very conservative balance sheet (TTM debt-to-equity ~0.06, ROE ~12%). Offsets include moderating recent revenue growth and some cash-conversion variability (operating cash flow coverage below 1x; TTM free cash flow slightly down year over year) despite consistently positive FCF.
Income Statement
84Very PositiveBalance Sheet
90Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.69T | 2.47T | 2.33T | 2.02T | 1.74T | 1.50T |
| Gross Profit | 1.94T | 1.77T | 1.67T | 1.41T | 1.17T | 1.00T |
| EBITDA | 624.48B | 611.24B | 522.98B | 389.45B | 279.83B | 231.43B |
| Net Income | 387.60B | 363.15B | 343.12B | 121.62B | 133.91B | 125.46B |
Balance Sheet | ||||||
| Total Assets | 4.32T | 4.20T | 3.74T | 3.36T | 3.10T | 2.82T |
| Cash, Cash Equivalents and Short-Term Investments | 505.43B | 534.64B | 426.17B | 513.34B | 471.63B | 410.68B |
| Total Debt | 191.49B | 227.97B | 189.38B | 214.19B | 194.16B | 212.45B |
| Total Liabilities | 1.04T | 1.10T | 961.08B | 924.92B | 840.26B | 775.72B |
| Stockholders Equity | 3.22T | 3.03T | 2.73T | 2.39T | 2.23T | 2.01T |
Cash Flow | ||||||
| Free Cash Flow | 315.09B | 315.74B | 259.08B | 192.50B | 150.90B | 176.41B |
| Operating Cash Flow | 418.86B | 403.58B | 354.64B | 283.23B | 211.85B | 228.86B |
| Investing Cash Flow | -256.72B | -162.56B | -268.27B | -190.63B | -81.58B | -95.29B |
| Financing Cash Flow | -196.98B | -136.37B | -186.89B | -60.17B | -95.47B | -95.84B |
Otsuka Holdings Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4578, the sentiment is Positive. The current price of 12015.00 is above the 20-day moving average (MA) of 11990.25, above the 50-day MA of 11847.10, and above the 200-day MA of 10927.07, indicating a bullish trend. The MACD of 177.23 indicates Positive momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 26.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4578.
Otsuka Holdings Co Peers Comparison
Overall Rating
JP:451983Outperform- JP:457877Outperform
JP:452372Outperform
JP:450268.15Neutral
JP:456868Neutral
JP:450364Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4519 | 83Outperform | JPY 11.23T | 22.29 | 25.03% | 3.12% | 16.53% | 26.83% |
| JP:4578 | 77Outperform | JPY 6.31T | 16.32 | 12.31% | 1.41% | 11.33% | -12.64% |
| JP:4523 | 72Outperform | JPY 1.42T | 33.66 | 4.77% | 3.17% | 6.73% | -15.79% |
| JP:4502 | 68Neutral | JPY 10.62T | 27.16 | 5.07% | 3.04% | 6.25% | 15.40% |
| JP:4568 | 68Neutral | JPY 5.01T | 20.85 | 16.51% | 3.23% | 16.98% | 9.22% |
| JP:4503 | 64Neutral | JPY 4.63T | 12.62 | 20.41% | 3.07% | 16.93% | 347.13% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4578 | Otsuka Holdings Co | 12015.00 | 3758.12 | 45.51% | |
| JP:4503 | Astellas Pharma | 2571.00 | 1008.62 | 64.56% | |
| JP:4519 | Chugai Pharmaceutical Co | 6822.00 | -42.30 | -0.62% | |
| JP:4568 | Daiichi Sankyo Company | 2754.00 | -802.20 | -22.56% | |
| JP:4523 | Eisai Co | 5052.00 | 628.79 | 14.22% | |
| JP:4502 | Takeda Pharmaceutical Co | 6651.00 | 2639.32 | 65.79% |
Otsuka Holdings Co Corporate Events
Otsuka Holdings to Shift Governance Structure to Audit and Supervisory Committee Model
Otsuka Holdings Co., Ltd. has resolved at its Board meeting to transition from a Company with an Audit & Supervisory Board to a Company with an Audit and Supervisory Committee, subject to shareholder approval at its 19th Annual General Meeting in...
Otsuka Holdings Completes ¥50 Billion Share Buyback and Plans Cancellation of Treasury Shares
Otsuka Holdings Co., Ltd., a major Japanese healthcare conglomerate listed on the Prime Market of the Tokyo Stock Exchange, oversees a broad mix of pharmaceutical and nutraceutical businesses serving both domestic and international markets. As a list...
Otsuka Lifts Nine-Month Profits, Ups Dividend and EPS Outlook on Share Buybacks
Otsuka Holdings reported robust consolidated results for the nine months to September 30, 2026, with revenue up 12.3% to ¥2.04 trillion and business profit rising 19.2%, while profit attributable to owners increased 8.2%, supported by strong cor...
Otsuka’s VOYXACT Delivers Landmark Phase 3 Results in IgA Nephropathy
Otsuka Holdings Co., Ltd. operates a global healthcare business centered on innovative pharmaceuticals, with group companies Otsuka Pharmaceutical Co. and Otsuka Pharmaceutical Development & Commercialization, Inc. driving drug development and co...
Otsuka Seeks Full U.S. Approval for IgA Nephropathy Drug VOYXACT
Otsuka Pharmaceutical’s U.S. subsidiary has completed a rolling submission of a supplemental Biologics License Application to the U.S. FDA, seeking traditional approval for VOYXACT (sibeprenlimab). The drug previously received accelerated appro...
Otsuka Unit Taiho Advances Zipalertinib NDA for EGFR Exon 20 NSCLC Under FDA RTOR
Taiho Pharmaceutical, an Otsuka Holdings subsidiary, has begun submitting a New Drug Application to the U.S. Food and Drug Administration for zipalertinib combined with platinum-based chemotherapy in first-line treatment of locally advanced or metast...
Otsuka Holdings Nears Limit of ¥50 Billion Share Buyback Program
Otsuka Holdings has reported progress on its share repurchase program authorized by its board in February 2026, conducted under Japan’s Companies Act. Between September 1 and September 30, 2026, the company bought back 701,700 shares of its com...
Otsuka’s Zipalertinib Combo Delivers Strong Phase 3 Lung Cancer Results
Otsuka’s subsidiaries Taiho Pharmaceutical and Taiho Oncology, together with Cullinan Therapeutics, reported positive Phase 3 data for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion mutation-positive non-small cell lung canc...
Otsuka Holdings Advances ¥50 Billion Share Buyback Program
Otsuka Holdings has continued its previously approved share repurchase program, buying back 465,800 shares of common stock on the Tokyo Stock Exchange between August 1 and August 31, 2026, for a total of about ¥5.6 billion. These purchases form...
Otsuka’s Zipalertinib Combo Hits Phase 3 Goal in Targeted Lung Cancer Trial
Taiho Pharmaceutical and Taiho Oncology, key units of Otsuka Holdings, alongside Cullinan Therapeutics, reported that their global Phase 3 REZILIENT3 trial in first-line EGFR exon 20 insertion mutation non-small cell lung cancer met its primary endpo...
Otsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy
Otsuka reported new Phase 3 VISIONARY data showing its IgA nephropathy drug VOYXACT (sibeprenlimab-szsi) stabilized kidney function decline to near physiologic levels over two years, with an annualized eGFR slope of +0.3 mL/min/1.73 m²/year vers...
Otsuka Holdings Continues Share Buybacks Under ¥50 Billion Authorization
Otsuka Holdings has continued its share repurchase program authorized by its board in February 2026, buying back 317,900 common shares for approximately ¥3.52 billion between July 1 and July 31 through market purchases on the Tokyo Stock Exchang...
Otsuka Lifts 2026 Earnings Outlook and Raises Dividends on Strong Drug Sales
Otsuka Holdings has sharply raised its full-year 2026 consolidated forecast after strong first-half results, driven by steady growth of key drugs REXULTI, LONSURF and VOYXACT and delayed generic competition for JYNARQUE in the U.S. and ABILIFY MAINTE...
Otsuka Holdings Delivers Strong Half-Year Earnings and Lifts 2026 Dividend Forecast
Otsuka Holdings reported strong results for the six-month period ended June 30, 2026, with revenue rising 12.8% year-on-year to ¥1,332.4 billion and business profit up 17.3%, supported by higher operating profit and a 24.3% jump in profit attrib...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026